CSS
DSGN icon

Cubist Systematic Strategies’s Design Therapeutics DSGN Stock Holding History

Cubist Systematic Strategies’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,497
Closed -$78.7K – 3099
2024
Q2 		$78.7K Buy
23,497
+10,113
+76% +$39.4K ﹤0.01% 2660
2024
Q1 		$53.9K Sell
13,384
-44,297
-77% -$118K ﹤0.01% 3367
2023
Q4 		$153K Buy
57,681
+30,744
+114% +$70.4K ﹤0.01% 3080
2023
Q3 		$63.6K Sell
26,937
-39,749
-60% -$185K ﹤0.01% 3002
2023
Q2 		$420K Sell
66,686
-111,598
-63% -$683K ﹤0.01% 2490
2023
Q1 		$1.03M Buy
178,284
+68,981
+63% +$516K 0.01% 2167
2022
Q4 		$1.12M Buy
+109,303
New +$1.48M 0.01% 2341

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cubist Systematic Strategies's DSGN Position: Q3 2024 in Review

Cubist Systematic Strategies sold out of Design Therapeutics (DSGN) in Q3 2024, closing a stake of 23,497 shares — an estimated $78.7K sold.

Cubist Systematic Strategies first reported a position in DSGN in Q4 2022 and held it in 7 quarters. The position peaked at $1.12M in Q4 2022. 100 funds tracked by Wall St. Rank hold DSGN as of Q3 2024.

  • Cubist Systematic Strategies reported no remaining Design Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 23,497 Design Therapeutics shares in Q3 2024, an estimated $78.7K.
  • Cubist Systematic Strategies first reported a position in Design Therapeutics in Q4 2022 and held it in 7 quarters.
  • Cubist Systematic Strategies's Design Therapeutics position peaked at $1.12M in Q4 2022.
  • 100 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2024.

Based on Cubist Systematic Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.